Hormone replacement therapy in an anti-ageing strategy for men

Journal of the British Menopause Society

Volumn 8, Issue 2, 2002, Pages 50-56

  Comhaire, Frank ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Andropause; Hormone replacement therapy; Male ageing; Quality of life; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CHOLESTEROL; CORTICOTROPIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HORMONE; MELATONIN; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL;

AGING; CIRCADIAN RHYTHM; DRUG EFFECT; HEMATOCRIT; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MALE; MALE INFERTILITY; NEUROENDOCRINE DISEASE; REVIEW; SUSTAINED DRUG RELEASE; TESTIS FUNCTION; TESTOSTERONE BLOOD LEVEL;

EID: 0036068603     PISSN: 13621807     EISSN: None     Source Type: Journal    
DOI: 10.1258/136218002100321659     Document Type: Review

References (76)

1. Death and the research imperative
2. Telomere biology in human aging and aging syndromes
3. Mitochondrial involvement in brain function and dysfunction: Relevance to aging, neurodegenerative disorders and longevity
4. Presence of melatonin in the human hepatobiliary-gastrointestinal tract
5. Localization and physiological significance of gastrointestinal melatonin
6. Muscle, metabolism and melatonin
7. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation
8. Glucocorticoid-induced impairment in declarative memory performance in adult humans
9. DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology
10. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial
11. DHEA deficiency syndrome: A new term for old age?
12. Endocrine aspects of ageing in the male
13. Serum inhibin B levels in community-dwelling elderly men
14. Testosterone, body composition and aging
15. Age-related changes in plasma dehydroepiandrosterone sulphate, cortisol, testosterone and free testosterone circadian rhythms in adult men
16. A new 'aging males' symptoms rating scale
17. Validation of a screening questionnaire for androgen deficiency in aging males
18. Andropause: Hormone replacement therapy in the ageing male
19. Serum leptin levels in healthy ageing men: Are decreased serum testosterone and increased adiposity in elderly men the consequence of leptin deficiency?
20. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension
21. Osteoporosis and osteoporotic fractures in men: A clinical perspective
22. Osteoporosis in the aging population: The male perspective
23. Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model
24. Testosterone supplementation for erectile dysfunction: Results of a meta-analysis
25. Entrainment of free-running circadian rhythms by melatonin in blind people
26. Abnormal melatonin secretion in male patients with hypogonadism
27. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: A 24-hour study
28. Melatonin and cancer treatment
29. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women
30. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults
31. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure
32. Incidence of malignant tumors in patients with acromegaly
33. Mortality and cancer incidence in acromegaly: A retrospective cohort study. United Kingdom Acromegaly Study Group
34. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men
35. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men
36. Do DHEA/DHEAS play a protective role in coronary heart disease?
37. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study
38. Adrenal steroids in human prostatic cancer cell lines
39. Is there a case for DHEA replacement?
40. A critical evaluation of simple methods for the estimation of free testosterone in serum
41. Androgen deficiency in aging men
42. Environmental and dietary endocrine disrupters and women's health
43. Effects of testosterone on the behavior of male cynomolgus monkeys (Macaca fascicularis)
44. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men
45. One and the same androgen for all? Towards designer androgens
46. Dihydrotestosterone: A rationale for its use as a non-aromatizable androgen replacement therapeutic agent
47. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men
48. Long-term transdermal dihydrotestosterone therapy: Effects on pituitary gonadal axis and plasma lipoproteins
49. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men
50. Pharmacokinetic characteristics, efficacy, and safety and buccal testosterone in hypogonadal males: A pilot study
51. Buccal absorption of testosterone and its esters using a bioadhesive tablet in dogs
52. Androgen replacement therapy in the aging male - A critical evaluation
53. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression
54. Effects of testosterone replacement in hypogonadal men
55. Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men
56. Long-term effect of testosterone therapy on bone mineral density in hypogondal men
57. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis
58. Lower androgenicity is associated with higher plamsa levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men
59. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study
60. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism
61. Acute anti-ischemic effect of testosterone in men with coronary artery disease
62. Effect of testosterone administration on upper airway collapsibility during sleep
63. Effects of androgen deficiency and replacement on prostate zonal volumes
64. Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France
65. Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men
66. Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins
67. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction
68. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men
69. Testosterone: Its role in development of prostate cancer and potential risk from use as hormone replacement therapy
70. High-grade prostate cancer is associated with low serum testosterone levels
71. Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity
72. On the prevention and therapy of prostate cancer by androgen administration
73. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers
74. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial
75. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer
76. Prevention of prostate-related cancers in Lobund-Wistar rats